VivoSim Labs regains Nasdaq compliance, boosts cash
VivoSim Labs, Inc. reported that the Nasdaq Listing Qualifications Staff has determined the company now complies with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2.5 million.
Rhea-AI Filing Summary
VivoSim Labs, Inc. reported that the Nasdaq Listing Qualifications Staff has determined the company now complies with Nasdaq Listing Rule 5550(b)(1), which requires minimum stockholders’ equity of $2.5 million. After filing its Form 10-K for the year ended March 31, 2026, VivoSim received a $5.0 million milestone payment and a further $1.0 million escrow release from Eli Lilly related to a prior FXR program sale, and completed a July 17, 2026 financing issuing pre-funded and common warrants at $0.85 per underlying share for $4.0 million in gross proceeds.
These July events are not reflected in previously filed annual or upcoming quarterly financial statements. As of August 3, 2026, cash on hand was approximately $10.1 million. Common shares outstanding increased from 3,194,295 on June 30, 2026 to 13,390,789 on August 3, 2026, driven by warrant exercises. VivoSim reiterated guidance that it anticipates 500%+ revenue growth in Fiscal Year 2027 as it expands contract research services using its NAM 3D human tissue models for pharmaceutical customers.
Positive
- Regains Nasdaq equity compliance: Nasdaq staff notified VivoSim that it currently complies with Listing Rule 5550(b)(1), removing an immediate listing-compliance overhang tied to minimum stockholders’ equity.
- Stronger liquidity position: Cash on hand reached approximately $10.1 million as of August 3, 2026, supported by a $5.0 million Eli Lilly milestone, $1.0 million escrow release, and a $4.0 million warrant financing.
- Very aggressive growth outlook: The company reiterated guidance that it anticipates 500%+ revenue growth in Fiscal Year 2027 from marketing its NAM-based contract research services.
Negative
- None.
Filing Explained
The August 6 Form 8-K furnishes, rather than files, a press release with preliminary management estimates: its $10.1 million cash figure and other updates supplement, but do not replace, audited or upcoming quarterly financial statements.
8-K Event Classification
Key Figures
Key Terms
Nasdaq Listing Rule 5550(b)(1) regulatory
pre-funded warrants financial
New Approach Methodologies (NAM) medical
forward-looking statements regulatory
FXR program medical
Earnings Snapshot
The company reiterates that it anticipates 500%+ revenue growth in Fiscal Year 2027 based on progress marketing its NAM-based contract research services.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did VivoSim Labs (VIVS) announce regarding its Nasdaq listing status?
How much cash does VivoSim Labs (VIVS) report having on hand and how was it funded?
What revenue growth guidance did VivoSim Labs (VIVS) reiterate for Fiscal Year 2027?
What financing transaction did VivoSim Labs (VIVS) complete in July 2026?
What is the business focus of VivoSim Labs (VIVS) mentioned in this update?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 6, 2026, VivoSim Labs, Inc., a Delaware corporation (the “Company”), issued a press release announcing, among other things, that (i) the Listing Qualifications Staff of The Nasdaq Stock Market LLC notified the Company that the Staff has determined that the Company currently complies with Nasdaq Listing Rule 5550(b)(1), which requires registrants to maintain a minimum stockholders’ equity balance of $2.5 million, (ii) the Company’s preliminary cash on hand as of August 3, 2026 was approximately $10.1 million, and (iii) the Company anticipates 500%+ revenue growth in its fiscal year 2027. This information, as well as a copy of the press release, which is furnished herewith as Exhibit 99.1, is incorporated by reference herein. The preliminary financial information presented in the press release reflects the Company’s current estimates based on information available as of the date hereof and has been prepared by the Company’s management and could be impacted by the effects of financial closing procedures, final adjustments and other developments.
The information in this Item 2.02, including the press release attached hereto as Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “1934 Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the 1934 Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Number |
|
Description |
99.1 |
|
Press Release, dated August 6, 2026. |
104 |
|
Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). |
|
|
|
* * *
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
VivoSim Labs, Inc. |
|
|
|
|
Date: |
August 6, 2026 |
By: |
/s/ Norman Staskey |
|
|
|
Name: Norman Staskey |
Exhibit 99.1
VivoSim Provides Financial and Listing Compliance Update
San Diego, CA — August 6, 2026 — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, today announced that on August 4, 2026, we received notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC indicating that the Company has regained compliance with Nasdaq Listing Rule 5550(b)(1) which requires registrants to maintain a minimum stockholders’ equity of $2.5M.
Subsequent to the filing of its recent Annual Report on Form 10-K for the fiscal year ended March 31, 2026, filed with the SEC on July 14, 2026 (the “Form 10-K”), the Company received a $5.0 million milestone payment from Eli Lilly and Company, and $1.0 million of additional cash was released from escrow on July 22, 2026, both in connection with the Company’s previous sale of its FXR program to Eli Lilly and Company. The Company also completed a financing on July 17, 2026, issuing pre-funded warrants and common warrants at a combined purchase price of $0.85 per share of common stock underlying the pre-funded warrants and received gross proceeds of $4.0 million, with net proceeds of approximately $3.6 million.
The Company is drawing attention to these events because the timing of the events means they were not reflected in the Company’s audited financial statements for the year ended March 31, 2026 included in Form 10-K and will not be in the financial statements in the Company’s upcoming Quarterly Report on Form 10-Q filing for the period ended June 30, 2026.
As of August 3, 2026, the Company’s cash on hand was approximately $10.1 million. Due to the significant events described above that occurred in July after the close of both the last fiscal year, the year ended March 31, 2026 and the first quarter of this fiscal year 2027, the quarter ending June 30, 2026, the Company is providing this additional information to investors in order to complement the financial statements previously included in the Company’s annual and quarterly filings with the SEC in order to provide stockholders and the public with updated information.
As of June 30, 2026, the Company had 3,194,295 shares of common stock outstanding, and as of August 3, 2026, the Company had 13,390,789 shares of common stock outstanding, which reflects 9,896,718 shares of common stock issued between July 15, 2026 and July 31, 2026 upon exercise of certain warrants to purchase common stock.
The Company reiterates its previously announced guidance that it anticipates 500%+ revenue growth in Fiscal Year 2027 given its progress in marketing contract research services using NAMs models to pharmaceutical companies.
Preliminary Financial Information
The unaudited financial information presented in this press release is preliminary and may change. The Company undertakes no obligation to update or supplement the information provided in this press release. The preliminary financial information included in this press release reflects the Company’s current estimates based on information available as of the date hereof and has been prepared by the Company’s management. This preliminary financial information should not be viewed as a substitute for full financial statements prepared in accordance with the Generally Accepted Accounting Principles and is not necessarily indicative of the results to be achieved for any future periods. This preliminary financial information could be impacted by the effects of financial closing procedures, final adjustments and other developments.
About VivoSim Labs
VivoSim Labs, Inc. (“VivoSim” and the “Company”), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional (“3D”) human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies (“NAM”) models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration (“FDA”) Roadmap to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit www.vivosim.ai.
Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding the Company’s cash on hand, revenue growth guidance and the Company’s progress in marketing contract research services using NAMs models to pharmaceutical companies. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company’s filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on July 14, 2026. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events.
Contact(s):
Investor Relations
info@vivosim.ai
VivoSim Labs, Inc.